Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit

Annovis Bio

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) is set to participate in the 13th Alzheimer’s & Parkinson’s Drug Development Summit, taking place March 18-20 in Boston, Massachusetts. The company will highlight its latest advancements in neurodegenerative disease treatments, presenting new insights into its lead drug candidate, buntanetap, and emphasizing the importance of a more comprehensive approach to targeting neurotoxic proteins.

Maria Maccecchini, Ph.D., Founder and CEO of Annovis, will lead the company’s contributions to the summit on March 19. She will deliver a presentation titled “Highlighting Phase III Buntanetap Data & Embracing a More Holistic Approach to Neurodegenerative Disease Targeting” at 3:30 PM EST. Her talk will explore the mechanisms behind buntanetap’s ability to address alpha-synuclein and other neurotoxic proteins, an approach that aims to overcome the challenges posed by narrowly focused therapies in the field of neurodegenerative disease.

Following the presentation, Dr. Maccecchini will join a panel discussion at 4:30 PM EST, titled “Exploring Opportunities in Alpha-Synuclein & Beyond for More Transformative & Efficacious Therapies.” The discussion will focus on the future of drug development for Parkinson’s disease and the broader potential of multi-targeted approaches in therapeutic innovation.

The Alzheimer’s & Parkinson’s Drug Development Summit serves as a critical platform for driving progress in addressing the complexities of neurodegenerative diseases. With its end-to-end focus on drug discovery and late-stage development, the conference attracts leading experts dedicated to advancing the pursuit of novel therapeutic targets.

Annovis Bio’s participation aims to spotlight the company’s ongoing efforts in targeting alpha-synuclein, a protein closely associated with the development of Parkinson’s disease. By targeting this key player in disease progression, Annovis Bio hopes to revolutionize treatment options and provide more effective solutions for patients.

READ:  Ecovyst to Acquire Sulfuric Acid Production Assets from Cornerstone Chemical

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.